Implementing Quality by Design-A methodical approach in the RP-HPLC method development process by Ayre, Anita et al.
International Journal of Advances in Pharmaceutical Analysis 
IJAPA Vol. 4 Issue 1 (2014) 01-06 
Journal Home Page http://www.ijapa.ssjournals.com  
 
 
Corresponding Author*: anitaayre@gmail.com                                                                                  1 
 
Implementing Quality by Design-A methodical approach in the RP-HPLC 
method development process 
 
Anita Ayre*, Priya Mane, Komal Ghude, Mayuri Nemade and Paraag Gide 
 
Department of Quality Assurance, Dr. L. H. Hiranandani College of Pharmacy, Smt. CHM Campus, 
Ulhasnagar, Thane, Maharashtra, India, Zip code: 421 003 
 
Abstract 
The concept of quality by design (QbD) has recently been adopted for the development of 
pharmaceutical processes to ensure a predefined product quality. Focus on applying the QbD concept to 
analytical methods has increased as it is fully integrated within pharmaceutical processes and especially in the 
process control strategy. Quality by design (QbD) refers to the achievement of certain predictable quality with 
desired and predetermined specifications. The QbD based method development helps in generating a design 
space and operating space with knowledge of all method performance characteristics and limitations and 
successful method robustness within the operating space. A very useful component of QbD is the 
understanding of factors and their interaction effects by a desired set of experiments. For the purpose of QbD 
for HPLC methods, robustness and ruggedness should be verified early in the method development stage to 
ensure method performance over the lifetime of the product. Quality-by-Design principles are applied to build 
in a more scientific and risk-based multi-factorial approach to the development and validation of analytical 
methods using HPLC. 
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1. Introduction 
Analytical method development, validation 
and transfer are key elements of any pharmaceuticals 
discovery, developmental program and 
manufacturing. Analytical techniques and tools 
require to define the quality of their products and to 
retain their qualification. The analytical tools include 
chemical, physico-chemical, instrumental, biological 
techniques and also the combination of different 
instrumental methods (hyphenated techniques) for 
developing qualitative and quantitative determination. 
Analytical testing also plays a prominent role in 
pharmaceutical development, risk assessment, process 
monitoring and control and continuous quality 
assessment throughout the product life cycle.
1
 The 
development and use of analytical methods evolve 
from generating information about a manufacturing 
process and product to using the methods for 
monitoring and controlling parameters that are critical 
to a drug‟s quality. The major challenge in analytical 
method development is HPLC method development 
for the analysis of drug substances. In the past, the 
common practice to develop an analytical method in 
liquid chromatography was performed by a trial and- 
error approach, for example by varying one-factor-at-
a-time (OFAT) and examine the resolution of peaks 
until the best method was found. This approach was 
time-consuming and required a large amount of 
manual data interpretation. It often resulted in a non-
robust performance when transferred into another lab 
because interactions between factors were not 
considered. 
2
 This problem has been now overcome 
by applying a Quality by Design (QbD) approach to 
the analytical method development. QbD is defined as 
“a systematic approach to development that begins 
with predefined objectives and emphasizes product 
and process understanding and process control, based 
on sound science and quality risk management”. QbD 
has been attracting increased attention in the 
development of analytical separation methods, 
because these are intended to be used for quality 
control and analysis of API and drug products, to 
ensure product quality and thus patient safety. 
3 
 
2. Regulatory aspects of QbD
4
 
2.1. ICH guideline: International conference on 
harmonization in its Q8 pharmaceutical development, 
Q9 quality risk assessment and Q10 pharmaceutical 
quality system gives stringent requirements regarding 
quality of product. The underlying principles of QbD 
i.e. science- and risk-based product development, risk 
assessment, lifecycle approach and method design are 
explained in the quality guidelines of international 
conference on harmonization i.e. ICH Q8 
Pharmaceutical Development, ICHQ9 Quality Risk 
Management, and ICH Q10 Pharmaceutical Quality 
System. 
2.2. FDA Perspective: FDA‟s view of QbD is “QbD 
is a systematic approach to product and process 
design and development,” This concept was accepted 
by FDA in 2004 and detail description was given in 
„pharmaceutical cGMPs for 21st century – a risk 
based approach‟. FDA also states importance of 
quality of pharmaceutical products by giving Process 
Analytical Technology (PAT) which is a Framework 
for Innovative Pharmaceutical Development, 
Manufacturing and Quality Assurance.     
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2. 3. Regulatory Challenges and inspection: In a 
QbD concept, the regulatory burden is less because 
there are wider ranges and limits based on product 
and process understanding. Changes within these 
ranges and limits do not require prior approval. 
Traditionally, inspections have been conducted using 
the FDA systems-based approach and in accordance 
with CDER‟s Compliance Program 7356.002M. 
During prelicense or preapproval inspections under a 
QbD concept, the FDA inspection team assesses the 
implementation and effectiveness of the process 
design as described in the application and whether 
knowledge and risk management have been 
transferred successfully from development to 
manufacturing. The inspection evaluates the quality 
system and its effectiveness regarding consistent 
product quality, change control procedures, process 
improvements, deviation management, and 
knowledge and risk management during the product 
lifecycle. But, design, testing, and monitoring 
programs that demonstrate robustness and consistency 
would be highlighted.  
2.4 QbD principles in method development 
process: The application of QbD principles to 
analytical method development is focused on the 
concept of building quality into the method during 
development, instead of testing methods for quality 
after development
5
. A very useful component of QbD 
is the understanding of factors and their interaction 
effects by a desired set of experiments. For the 
purpose of QbD for HPLC methods, robustness and 
ruggedness should be verified early in the method 
development stage to ensure method performance 
over the lifetime of the product. 
Two key concepts in implementation and 
understanding of QbD are: 
a. Design space 
b. Control strategy 
The knowledge obtained during development helps to 
justify the establishment of the design space and 
(process) controls.
6 
a. Design space (DS):  It is a key component of the 
development of analytical procedure   using QbD. In 
ICH        pharmaceutical-development guideline Q8, 
DS is defined as „„the multidimensional combination 
and interaction of input variables (e.g., material 
attributes) and process parameters that have been 
demonstrated to provide assurance of quality‟‟. 
Therefore, the multidimensional combination and 
interaction of input variable corresponds to a 
subspace, so-called the DS, where assurance of 
quality has been proved. „„Working within the design 
space is not considered as a change‟‟.7 The first step is 
to define the intended purpose of the analytical 
method. This has been called the Analytical Target 
Profile (ATP).  The method under development will 
then follow a risk assessment.
8
 The purpose of the 
risk assessment for LC methods is to develop high 
confidence that the method will meet all performance 
criteria under all conditions of use as it progresses 
through its lifecycle. A systematic approach is used 
for identifying all the potential method factors that 
may need to be controlled to ensure method 
performance.
6
 This systematic approach classifies 
risks in groups related to instrumentation, materials, 
methods, chemicals and reagents, measurements, 
human factors, environmental issues (e.g., laboratory 
temperature, relative humidity, and light).
8  
b. Control strategy: Nonetheless, the development 
of QbD analytical methods does not end with the DS. 
A control strategy of the method has to be 
implemented to assure that the method will perform 
as intended on a routine basis.
8
 The control strategy is 
obtained from the process understanding gained from 
modeling the design space. An analytical adaptation 
of control strategy is defined as the controls on input 
factors to a method that ensure the method meets both 
traditional system suitability criteria and wider 
performance-related goals.
5
  Here, elements from the 
DS can be used to select responses that have to be 
monitored at each analytical run. These responses that 
will be implemented in the control strategy are known 
as system-suitability tests or validity tests. They can 
be the definition of a minimum resolution  value 
between a critical pair, the acceptable value for tailing 
peaks, the maximum acceptable value expressed in 
RSD for the repeated analysis of a standard solution, 
the minimum value of the determination coefficient 
(R2) of a standard curve, and so on. 
9 
The QbD 
paradigm is employed to obtain better understanding 
of the effect of these factors on product stability in 
order to ensure the product stability throughout the 
expiry date.  
 
3. Implementing QbD-Practical approach 
a.Define the Design Space of analytical methods:  
The starting point is to gather and review all historical 
information available on the analytical method under 
development, previously developed methods that are 
closely related, and the literature and scientific 
information available on the subject.
8 
b. Define the Analytical target profile and Critical 
quality attributes: The analytical target profile 
(ATP) is a set of criteria that define what will be 
measured (e.g. the level of a specified impurity, % 
degradation in the sample) and the performance 
criteria to be achieved by the measurement (e.g. 
accuracy, precision and range).
10
 On the basis of 
ATP, different analytical methods and/or techniques 
are evaluated in a preliminary investigation to 
approach the method objective, in general with the 
purpose of achieving maximum selectivity with 
adequate efficiency, and improving the 
reproducibility and repeatability of measurements. 
After these preliminary experiments, the QbD 
workflow can start by defining quality target product 
profile (QTPP) and critical quality attributes (CQAs)
 
9
.QTPP is defined as a “prospective summary of the 
quality characteristics of a drug product that ideally 
will be achieved to ensure the desired quality, taking 
into account safety and efficacy of the drug product”. 
This definition to analytical methods means that, the 
separation objectives should be well defined. For e.g. 
Separation of API from the impurities/ degradation 
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product while meeting method performance criteria 
based on regulatory requirements. 
10
 
        CQAs are defined as „„a physical, chemical, 
biological or microbiological property or 
characteristic that should be within an appropriate 
limit, range, or distribution to ensure the desired 
product quality‟‟. The performance criteria can be 
called Critical Quality Attributes (CQAs) of the 
analytical method.  These CQAs are the responses 
that are measured to judge the quality of the 
developed analytical methods. For separative 
analytical methods like chromatography, the CQAs 
can be related to the method selectivity e.g., the 
resolution (RS). Additional CQAs can be the run time 
of the analysis, the precision of the analytical method, 
the lower limit of quantification or the dosing range 
of the analytical method. Sometimes these CQAs can 
be directly modeled through a multivariate (non-
)linear model. However in some situations, the 
modeled (primary) responses may differ from the 
CQAs. The CQAs are obtained after the modeling of 
these primary responses. For chromatographic 
methods, the usual key CQA is resolution of the 
critical pair. However, resolution depends upon the 
retention factor of the two chromatographic peaks 
involved, so several authors have proposed to model 
the retention factors instead of the resolution as the 
primary response. The resolution can subsequently be 
computed from these modeled responses.  
a.Set the Experimental factors, ranges and levels: 
To obtain the Design space of analytical methods, the 
choice of the experimental factors and their respective 
range is essential. From the whole experimental 
design region, the factors and the ranges that will 
affect the responses must be chosen. Depending on 
the knowledge space, formal designs of experiments 
must be performed. This investigated knowledge 
space is a multidimensional space that needs to be 
large enough to create response variations.  Generally, 
if no prior information about the response variation is 
known, preliminary experiments should be carried out 
to estimate the range and the magnitude of variation 
of each factor. 
8
 
b.Use of Design of Experiments (DoEs) and 
response modeling: Conventionally experiments 
were performed by considering one factor- at-a-time 
(OFAT) to gain knowledge about a process or to 
optimize it. OFAT generally requires a higher number 
of experiments to estimate the factors effect with 
good precision and their interactions can rarely be 
estimated. Application of statistical design of 
experiments is currently encouraged by the regulatory 
agencies, sometimes together with the use of 
chromatographic, modeling and optimization 
software. For automated method development, it is 
possible to use optimization softwares dedicated to 
RPLC. Some of these softwares are based on the 
famous linear solvent strength (LSS) theory  
including DryLab (Molnár Institute, Berlin, 
Germany), ACD/LC and GC Simulator (ACD/Labs, 
Toronto, Canada), ChromSword (ChromSword 
Group, Riga, Latvia), Osiris (Datalys, Grenoble, 
France) and Fusion AE (S -Matrix, Eureka, CA, 
United States)
 9
. Tyteca et al. introduced an 
innovative strategy, also based on LSS theory. They 
proposed a new algorithm able to automatically focus 
on the most promising areas of the solution space by 
shifting and stretching the elution window over 
different parts of the time-axis thanks to the 
information on the retention properties of the first and 
last peaks of the chromatogram.
11
 
Design Expert.
9
 DoEs provide an effective, 
efficient approach to evaluate simultaneously the 
effects of factors and their interactions and to model 
and to predict the relationship between these factors 
and the CQAs or responses. In recent years, it has 
proved to be a good alternative to automated 
softwares based on LSS for chromatographic method 
development. The selected DoE needs to have good 
statistical properties (e.g., orthogonality and/or 
rotatability), and should maintain the number of 
experiments as low as possible. It should also allow 
estimation of the experimental error and assessment 
of the validity of the model tested. Alexander & 
Molnar
2
 have developed a stability indicating UHPLC 
method for ebastine by using the chromatography 
modeling software DryLab
®
4 which allowed the 
visualization of a “Design Space”. The robustness of 
the developed method was studied by varying the six 
parameters: gradient time, temperature, ternary 
composition of the eluent, flow rate and start and end 
concentration of the gradient at 3 levels (+1, 0, −1). 
The resulting 729 experiments were performed in 
silico from the previously constructed model for 
Design Space and showed that the required resolution 
of 2.0 can be reached in all experiments. 
DoE can be split up into two main 
categories: screening designs and response-surface 
designs
8
 
i. Screening designs: Screening designs estimate the 
effects of factors on selected responses. When too 
many factors (four or more) seem to affect the 
responses and have been revealed by the FMEA 
prioritization, these designs can be used to select 
those having the largest effects on the responses. The 
remaining significant factors are studied in a 
subsequent DoE [e.g., method optimization]. In the 
screening category of designs, well known are the 
Plackett and Burman designs that study factors at two 
levels. In liquid chromatography (LC), Plackett and 
Burman designs are also used to estimate the 
robustness of an optimal separation. Other types of 
screening designs are fractional factorial designs, 
which generally do not allow understanding of a 
process under investigation if it may include 
interactions and higher order effect terms. However 
they are very useful in selecting the most important 
factors that influence the selected responses of the 
analytical method under investigation.
8
 
ii. Response-surface designs. The second category of 
DoE corresponds to designs used to predict and to 
optimize the responses. These DoEs are full factorial 
designs, central composite designs and Box-Benkhen 
and Doehlert designs. D-optimal designs can also be 
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selected in order to answer particular requirements 
(e.g., constraints on the levels of factors, or specific 
models). These designs are aimed at understanding 
the process under investigation. It involves 
understanding the relationship between the factors to 
assess the behavior of the response, and the effects on 
the response. These designs are used to find the 
combination of factors that predict the optimal 
response with good precision. More than two levels of 
each factor are usually required in order to fit 
quadratic or higher order terms {e.g., when pH is a 
factor in LC, it may be required to study pH up to the 
third-order term: pH+pH2+pH3}. Response-surface 
designs are key tools to define the DS of analytical 
methods. They study a large experimental domain, 
understanding the behavior of the responses and the 
CQAs with respect to the studied factors, and they 
provide a model to predict the value of the CQAs 
within the range of these levels of factors.
8
 
Sonawane and Gide
12 
have developed and 
validated a stability indicating HPLC method for the 
determination of rebamipide wherein they employed 
2
3
 full factorial design during forced degradation to 
determine significant factors responsible for 
degradation and to obtain optimal degradation 
conditions. On the basis of preliminary experiments 
three independent factors; strength of acid/alkali 
(Normality), irradiation time (min) and microwave 
power (Watt), each at two levels, were chosen as 
input (factors) and % degradation as output 
(response). 
In another example, Bianchini et al
13 
developed and validated a HPLC method for the 
determination of process realted impurities in pridinol 
mesylate wherein they optimized the composition of 
the mobile phase with the aid of a 3
2
 full factorial 
experimental design, prepared with nine 
chromatographic runs under different conditions, 
which included the pH of the aqueous phase and the 
percentage of organic phase as the independent 
variables (factors), each at three levels. Four 
responses, including the effects of both factors on the 
retention time of the first eluting peak, the resolution 
between each impurity and API, the length of the 
chromatography, at a flow rate of 1.0 mL min
−1
 and 
employing a C18 column, were studied. 
iii. Response modeling: The modeling of the 
responses can be realized in two main ways. The first 
involves a theoretical or mechanistic model that 
connects some of the factors to the responses {e.g., 
realized with software available to optimize 
chromatographic methods using the solvophobic 
theory or linear solvent-strength theory. However, 
most of the time, there are no theoretical models that 
include all the factors that may influence the 
responses and the analytical CQAs. In this case, 
empirical models can be fitted on the data obtained to 
link the responses and the factors studied. This is 
usually performed by fitting multiple linear equations 
of adequate polynomial degree, related to the number 
of factors selected. In some situations, it may also be 
required to fit non-linear models
8  
Table 1: Examples of the RP-HPLC method development approaches based on the QbD paradigm. 
Analytical 
methods 
Name of drug QbD tool used Authors Ref. 
No. 
Stability 
indicating 
assay 
Eletriptan 
hydrobromide  
Optimization using response surface 
methodology  
B. Jocic, M. Zecevic, L. Zivanovic, A. 
Protic, M. Jadranin, V. Vajs  
14 
Complex pain 
management drug 
product  
Optimization using Fusion AE software  S. Karmarkar, R. Garber, Y. Genchanok, S. 
george, X. Yang, R. Hammond  
15 
Luliconazole  Experimental design-optimization using 
Full Factorial design  
Sandeep sonawane, Paraag Gide  16 
Eberconazole 
nitrate 
Optimization using response surface 
methodology 
M. Vamsi Krishna , Rajendra N. Dash, B. 
Jalachandra Reddy, P. Venugopal, P. 
Sandeep, G. Madhavi 
17 
Impurity 
profiling  
Nimodipine  Optimization using response surface 
methodology  
P. Barmpalexis, F. I. Kanaze, E. 
Georgarakis  
18 
Pazopanib HCl  Impurity fate mapping  Ming-Ling Sun, David Q. Liu, Alireza S. 
Kord  
19 
Atomoxetine HCl  Experimental design-optimization using 
Fractional Factorial design  
Peter F. Gavin , Bemard A. Olsen  20 
 Ropinirole Face-centered central composite design 
(CCD) with 23 full factorial design, ±1 
star design  
B. Jancic-Stojanovic, A. Malenovic, D. 
Ivanovic, T. Rakic, M. Medenica 
21 
LC method  Model- Examplain 
HCl  
Chromatographic simulation  for routine 
RP-HPLC method development  
Phil Borman, John Roberts, Chris Jones, 
Melissa Hanna -Brown, Roman Szucs,  
Simon Bale  
22 
Method 
development 
and assay 
using RP-
HPLC  
Glipizide  Optimization using Fusion Design 
Expert  software  
Cijo M. Xavier, Kanakapura Basavaiah, K. 
B. Vinay, N. Swamy  
23 
Screening of 19 
anti-malarial 
drugs 
 Combined use of Design of experiments 
(DoE), independent component analysis 
(ICA) and design space (DS) 
B. Debrus, P. Lebrun, J. Mbinze 
Kindenge, F. Lecomte, A. Ceccato, G. 
Caliaro, J. Mavar Tayey Mbay, B. 
Boulanger, R.D. Marini, E. Rozet, Ph. 
Hubert 
24 
Method 
development 
using HPTLC 
& UV 
spectroscopy 
Propafenone 
Hydrochloride 
Assessment of Critical parameters Monika L. Jadhav and Santosh R. Tambe 25 
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2. Conclusion  
RP-HPLC method development by quality 
by design approach is a very useful approach. It 
reduces the time required for method development 
and the method which we obtain by applying this 
approach is robust. It reduces the number of trials. 
The knowledge built up during the development of 
complex methods (such as impurity profiling, stability 
indicating assay) is used to select methods that meet 
pre-defined, stringent performance criteria and goals.
5 
  
The potential benefits of using a QbD 
approach rather than using traditional „„one factor at a 
time‟‟ experimentation leads to a better understanding 
of the factor influencing chromatographic separation 
and hence the potential for simultaneous development 
of multiple methods. A few merits of the QbD 
approach are summarized as:  
 Greater confidence in the ability of the 
method to meet their intended purposes.  
 Improved process capability 
 Reduced process variability 
 Reduced manufacturing costs 
 Reduced process design and development 
time 
 Increased understanding of the relationship 
between process inputs and output(s) 
When dealing with a relatively high number 
of analytes (i.e. higher that 10), the development of 
specific and robust methods in reversed-phase liquid 
chromatography (RPLC) generally requires 
substantial time and effort, even for the most 
experienced chromatographers. In this context, QbD 
is preferred as an innovative and comprehensive 
approach to speed up and automate the method 
development process. Nonetheless, no current 
regulatory document provides adequate guidelines for 
a complete evaluation of the obtained DS quality as 
well as specific requirements for the robustness 
validation. Hence assessment of the complete method 
validation with an important degree of confidence 
according to QbD method development is the need of 
the hour.  
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